Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135689 | 0.82 | CDK2 (0.52) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| Tetrabuthylammonium SCHEMBL200612 | 0.78 | CDK2 (0.68) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| 6-O-Benzylguanine SCHEMBL10916356 | 0.75 | PIN1 (0.50) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL21316660 | 0.68 | CDK1 (0.40) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL12844134 | 0.68 | HEXA (0.37) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL8348019 | 0.66 | NLRP3 (0.40) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| Tetrabuthylammonium SCHEMBL6473273 | 0.66 | SLC22A1 (0.36) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL4551801 | 0.66 | ADORA2A (0.44) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL2938699 | 0.66 | PDPK1 (0.37) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL21684954 | 0.66 | CSNK2A1 (0.36) | CDK2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9005906-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140315979-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8796437-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2188298-B1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130211064-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8440803-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
| US-8088904-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2188298-A2 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | Isis Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009143369-A2 | METHOD OF PREPARING NUCLEOSIDES AND ANALOGS THEREOF WITHOUT USING CHROMATOGRAPHY | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009023855-A2 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | HNRNPH1, RNASEH1, SNRPE | CDK1 2888/4885CCNB1 2409/4885CDK2 2349/4885 |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | CDK1 2435/4885CCNB1 2843/4885CDK2 1068/4885 |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | CDK1 2435/4885CCNB1 2843/4885CDK2 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.